{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Dan+Carden&houseId=1&max-answer.questionFirstAnswered.=2019-05-22T14%3A13%3A03.24Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberPrinted.=Dan+Carden&houseId=1&max-answer.questionFirstAnswered.=2019-05-22T14%3A13%3A03.24Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Dan+Carden&houseId=1&_metadata=all&max-answer.questionFirstAnswered.=2019-05-22T14%3A13%3A03.24Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Dan+Carden&_page=0&houseId=1&max-answer.questionFirstAnswered.=2019-05-22T14%3A13%3A03.24Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Dan+Carden&houseId=1&max-answer.questionFirstAnswered.=2019-05-22T14%3A13%3A03.24Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Dan+Carden&houseId=1&max-answer.questionFirstAnswered.=2019-05-22T14%3A13%3A03.24Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1127173", "AnsweringBody" : [{"_value" : "Department for International Development"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1127173/answer", "answerText" : {"_value" : "
Action to avert, minimize and address loss and damage associated with climate change is intricately bound up with action on mitigation, adaptation, disaster risk reduction and disaster preparedness and response. We therefore do not see that attempting to define a separate category of finance for loss and damage as useful or practical. Of the £5.8bn on climate finance we have committed to spend from 2016-2021 the UK aims to spend 50% on adaptation and 50% on mitigation.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4137", "label" : {"_value" : "Biography information for Rory Stewart"} } , "answeringMemberConstituency" : {"_value" : "Penrith and The Border"} , "answeringMemberPrinted" : {"_value" : "Rory Stewart"} , "dateOfAnswer" : {"_value" : "2019-05-21", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-21T16:48:42.047Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "20"} , "answeringDeptShortName" : {"_value" : "International Development"} , "answeringDeptSortName" : {"_value" : "International Development"} , "date" : {"_value" : "2019-05-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Development Aid: Climate Change"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for International Development, pursuant to the Answer of 16 April 2019 to Question HL15044 on Developing Countries: Climate Change, how much of the £5.8 billion allocated to international climate finance between 2016-17 and 2020-21 will be spent on tackling loss and damage in climate-vulnerable countries.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4651", "label" : {"_value" : "Biography information for Dan Carden"} } , "tablingMemberConstituency" : {"_value" : "Liverpool, Walton"} , "tablingMemberPrinted" : [{"_value" : "Dan Carden"} ], "uin" : "255379"} , {"_about" : "http://data.parliament.uk/resources/1127214", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1127214/answer", "answerText" : {"_value" : "
The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.<\/p>
<\/p>
The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-21", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "255381"} , {"_value" : "255382"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-21T16:12:54.06Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Drugs: Prices"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the draft resolution for consideration by the World Health Assembly in May 2019 on improving the transparency of markets for medicines, vaccines and other health-related technologies, if the Government will withdraw its support for suggested amendments to remove every mention of high prices.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4651", "label" : {"_value" : "Biography information for Dan Carden"} } , "tablingMemberConstituency" : {"_value" : "Liverpool, Walton"} , "tablingMemberPrinted" : [{"_value" : "Dan Carden"} ], "uin" : "255380"} , {"_about" : "http://data.parliament.uk/resources/1127215", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1127215/answer", "answerText" : {"_value" : "
The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.<\/p>
<\/p>
The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-21", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "255380"} , {"_value" : "255382"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-21T16:12:54.12Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Drugs: Prices"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the draft resolution for consideration by the World Health Assembly in May 2019 on improving the transparency of markets for medicines, vaccines and other health-related technologies, if the Government will take steps to help ensure that the recommendation to member states calls for mandatory rather than voluntary measures.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4651", "label" : {"_value" : "Biography information for Dan Carden"} } , "tablingMemberConstituency" : {"_value" : "Liverpool, Walton"} , "tablingMemberPrinted" : [{"_value" : "Dan Carden"} ], "uin" : "255381"} , {"_about" : "http://data.parliament.uk/resources/1127216", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1127216/answer", "answerText" : {"_value" : "
The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.<\/p>
<\/p>
The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-21", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "255380"} , {"_value" : "255381"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-21T16:12:54.153Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Drugs: Prices"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if the Government will support the draft resolution for consideration by the World Health Assembly in May 2019 on improving the transparency of markets for medicines, vaccines and other health-related technologies.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4651", "label" : {"_value" : "Biography information for Dan Carden"} } , "tablingMemberConstituency" : {"_value" : "Liverpool, Walton"} , "tablingMemberPrinted" : [{"_value" : "Dan Carden"} ], "uin" : "255382"} , {"_about" : "http://data.parliament.uk/resources/1124738", "AnsweringBody" : [{"_value" : "Department for Education"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1124738/answer", "answerText" : {"_value" : "
The Public Health Outcomes Framework is a comprehensive source of data at local authority unitary, county and district level on the extent to which local strategies are successful and effective in improving outcomes for children in the early years. It is available at the following link: https://fingertips.phe.org.uk/profile/public-health-outcomes-framework<\/a>.<\/p> <\/p>